Abstract
The integration of artificial intelligence (AI) into the management of chronic obstructive pulmonary disease (COPD) and asthma offers significant advancements in patient care, diagnosis, and treatment personalization. AI technologies, particularly machine learning and deep learning, have shown great promise in predictive modeling, enabling earlier detection and more accurate diagnoses. AI-driven tools, such as telemedicine and remote monitoring applications, are helping clinicians provide personalized care and manage these conditions more effectively, especially for high-risk patients. Additionally, AI's ability to analyze vast datasets, including electronic health records and medical imaging, allows for more dynamic and adaptive treatment plans tailored to individual patients' needs. However, challenges remain, such as ensuring data privacy, addressing ethical concerns, and developing standardized regulatory frameworks to support the implementation of AI in clinical settings. Despite these challenges, the potential of AI to revolutionize COPD and asthma management is vast, and continued research and collaboration will be critical in overcoming these barriers and enhancing healthcare outcomes for patients worldwide.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research did not receive any specific funding from public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://doi.org/10.17632/9z8k2f95f6.1
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos